somatotroph is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
=== Classification === Epulis (literally, 'on the gingiva') is a general term for any gingival or alveolar tumor (i.e. lump on the gum). This term describes only the location of a lump and has no implication on the histologic appearance of a lesion. Epulis is also sometimes used synonymously with epulis fissuratum, however other conditions are classified as epulides, e.g. giant cell epulis (peripheral giant cell granuloma), ossifying fibroid epulis (peripheral ossifying fibroma), and congenital epulis.
For 0D MOF structures, polycationic nodes can act as semiconductor quantum dots which can be activated upon photostimuli with the linkers serving as photon antennae. Theoretical calculations show that MOFs are semiconductors or insulators with band gaps between 1.0 and 5.5 eV which can be altered by changing the degree of conjugation in the ligands. Experimental results show that the band gap of IRMOF-type samples can be tuned by varying the functionality of the linker. An integrated MOF nanozyme was developed for anti-inflammation therapy.
== Dissociation and equilibrium == Reactions of acids are often generalized in the form HA ⇌ H+ + A−, where HA represents the acid and A− is the conjugate base. This reaction is referred to as protolysis. The protonated form (HA) of an acid is also sometimes referred to as the free acid. Acid–base conjugate pairs differ by one proton, and can be interconverted by the addition or removal of a proton (protonation and deprotonation, respectively). The acid can be the charged species and the conjugate base can be neutral in which case the generalized reaction scheme could be written as HA+ ⇌ H+ + A. In solution there exists an equilibrium between the acid and its conjugate base. The equilibrium constant K is an expression of the equilibrium concentrations of the molecules or the ions in solution. Brackets indicate concentration, such that [H2O] means the concentration of H2O. The acid dissociation constant Ka is generally used in the context of acid–base reactions. The numerical value of Ka is equal to the product (multiplication) of the concentrations of the products divided by the concentration of the reactants, where the reactant is the acid (HA) and the products are the conjugate base and H+.
Iraq's government made no secret that it would attack Israel if invaded. Prior to the war's start, in the aftermath of the failed US–Iraq peace talks in Geneva, Switzerland, a reporter asked Iraq's English-speaking foreign minister and deputy prime minister Tariq Aziz: "Mr. Foreign Minister, if war starts ... will you attack Israel?" His response was: "Yes, absolutely, yes." Five hours after the first attacks, Iraq's state radio broadcast declared that "The dawn of victory nears as this great showdown begins." Iraq fired eight missiles the next day. These missile attacks were to continue throughout the war. Iraq fired 88 Scud missiles during the war's seven weeks. Iraq hoped to provoke a military response from Israel. The Iraqi government hoped that many Arab states would withdraw from the Coalition, as they would be reluctant to fight alongside Israel. Following the first attacks, Israeli Air Force jets were deployed to patrol the northern airspace with Iraq. Israel prepared to militarily retaliate, as its policy for the previous 40 years had always been retaliation. However, President Bush pressured Israeli prime minister Yitzhak Shamir not to retaliate and withdraw Israeli jets, fearing that if Israel attacked Iraq, the other Arab states would either desert the coalition or join Iraq. It was also feared that if Israel used Syrian or Jordanian airspace to attack Iraq, they would intervene in the war on Iraq's side or attack Israel. The coalition promised to deploy Patriot missiles to defend Israel if it refrained from responding to the Scud attacks.
Sources: en.wikipedia.org
According to Future Forward PAC, a derivative of his campaign's "Kamala is for they/them, President Trump is for you" attack ad (with commentary by Charlamagne tha God spliced in) was one of the most effective of the campaign, shifting the race 2.7 percentage points in favor of Trump after viewers watched it. However, findings from an RCT study released by Ground Media/GLAAD said that the ad did not have an impact on who viewers intended to vote for.
===== Flutamide ===== There is tentative evidence for flutamide in women; however, it is associated with relatively high rates of liver problems and strong recommendations have been made against its use. Like spironolactone, flutamide is typically only used by women. Bicalutamide is another option for the treatment of female pattern hair loss. It has a far lower risk of liver toxicity than flutamide and is said to have an excellent safety profile. However, bicalutamide retains a small risk of liver toxicity and for this reason periodic liver monitoring is recommended during treatment.
What a terrible shame. It would be easy for me to get in a back room with this man's lawyer and make this go away, but there are some moments in life when you have to stand up and defend your honor against the evil in this world. I will not tolerate this heartless attempt to exploit me or the woman I loved. Cat's troubles were born long before I met her and sadly her tragic end was beyond anyone's control. I really hope that some day soon people will stop trying to profit from this and let her rest in peace. In October 2016, White's mother, Brigid Sweetman, also filed a wrongful death lawsuit against Carrey. Both lawsuits were dismissed on January 25, 2018, and attorneys for both sides confirmed there would be no further legal proceedings.
Miyabi Sanekazura (真葛美 夜日, Sanekazura Miyabi) Head maid of the Town of Autumn Domestic Affairs Department. She is Nadeshiko's maid and works at the village's main shrine. She is strong-willed, caring, and skilled at her job. She can't help but love Nadeshiko and is happy to have been chosen as her head maid. Her family situation is a bit complicated. Koyoi Shirahagi (白萩 今宵, Shirahagi Koyoi) Member of the Town of Autumn's security. He is one of Rindo's closest subordinates and associates. He is a quiet, simple, and kind boy who takes care of Nadeshiko, but the little girl's guard dog does not seem to appreciate him and he often ends up being the victim of its pranks.
=== Early ventures === Johnson launched three startups between 1999 and 2003. The first one sold cell phones and helped pay his way through Brigham Young University. Johnson hired other university students to sell service plans and cell phones; Johnson earned about a $300 commission on each sale. He also started two other businesses. Inquist, a VoIP company Johnson co-founded with three other partners, combined features of Vonage and Skype. It ended operations in 2001. After that, he joined his brother and another partner on a $70 million real estate project in 2001. The project did not meet its sales goals.
Sources: en.wikipedia.org
United States civil aviation incidents are investigated by the National Transportation Safety Board (NTSB). NTSB officials piece together evidence from the crash site to determine likely cause, or causes. The NTSB also investigates overseas incidents involving US-registered aircraft, in collaboration with local investigative authorities, especially when significant loss of American lives occurs, or when the involved aircraft is American-built. In Venezuela, the organization tasked with investigating aviation accidents is the Ministry of Aquatic and Air Transport, more specifically the Directorate General for the Prevention and Investigation of Aeronautical Accidents.
=== RTG (radioisotope thermoelectric generator) power generation === As 241Am has a roughly similar half-life to 238Pu (432.6 years Am-241, 87.7 years Pu-238, decay energies nearly the same), it has been proposed as an active isotope of radioisotope thermoelectric generators, for use in spacecraft. Even though americium-241 produces less heat and electricity than plutonium-238 (the power yield is 114.7 milliwatts per gram [3.25 watts per ounce] for 241Am vs. 570 mW/g [16 W/oz] for 238Pu) and its radiation poses a greater threat to humans owing to gamma emission, it has advantages for long duration missions with its significantly longer half-life. The European Space Agency is working on RTGs based on americium-241 for its space probes as a result of the global shortage of plutonium-238 and easy access to americium-241 in Europe from nuclear waste reprocessing. Its shielding requirements in an RTG are the second lowest of all possible isotopes: only 238Pu requires less. An advantage over 238Pu is that it is produced as nuclear waste already. Prototype designs of 241Am RTGs expect 2–2.2 We/kg for a 5–50 We design, putting 241Am RTGs at parity with 238Pu RTGs within that power range, as the vast majority of the mass of an RTG is not the radioisotope, but the thermoelectrics, radiators, and isotope containment mass.
== Description == The cap is 1.5–4 centimetres (1⁄2–1+1⁄2 in) across, dry, at first hemispheric, expanding to campanulate or convex, with an incurved margin when young. Young caps start out light brown and fade to off-white or light gray at maturity, sometimes with yellowish or brownish tones. Often developing cracks in dry weather, slightly hygrophanous, turning greenish or blue where damaged. The gills are broadly adnate to adnexed, close, starting out gray and turning black as the spores mature. The gill faces have a mottled appearance and the edges are white. The spore print is black. The stipe is 6–12 cm long by 2 to 4 mm thick, equal to slightly enlarged at the base, pruinose, colored like the cap, staining somewhat blue where bruised. The taste and odor are farinaceous.
Record league victory: 9–0 v Loughborough, Second Division, 28 January 1899 v Accrington Stanley (away), Third Division North, 3 February 1934 Record cup victory: 6–0 v Blackpool, FA Cup first round, 20 January 1910 Record league defeat: 9–0 v Notts County, Second Division, 19 January 1927 Record cup defeat: 8–1 v Derby County, FA Cup first round, 30 January 1897 7–0 v Manchester United, EFL Cup third round, 17 September 2024 Most appearances: Barry Murphy, 569 Most goals scored for the club: Ernie Hine, 131 Most league goals scored in a season: Cecil McCormack, 33, 1950–51 Second Division Most international caps: Gerry Taggart, 35, Northern Ireland Record transfer fee received: £5,000,000 from Swansea City for Alfie Mawson (2017) Record transfer fee paid: £1,500,000 to Partizan Belgrade for Georgi Hristov (1997) and £1,500,000 to QPR for Mike Sheron (1999) Record attendance: 40,255 v Stoke City, FA Cup fifth round, 15 February 1936 Youngest ever Football League player: Reuben Noble-Lazarus, 15 years and 45 days Oldest player: Mike Pollitt, 41 years, 5 months and 30 days Most goals scored in a single game: 5; Frank Eaton v South Shields, 1927 Peter Cunningham v Darlington, 1933 Beaumont Asquith v Darlington, 1938 Cecil McCormack v Luton Town, 1950 Barnsley have spent more seasons and played more games at the second level of English football than any other team.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.